Cramer Rosenthal Mcglynn LLC Has $7.70 Million Stake in Omnicell, Inc. $OMCL

Key Points

• Cramer Rosenthal Mcglynn LLC increased its stake in Omnicell, Inc. by 27.3% in Q1, owning approximately 220,276 shares valued at $7.7 million.
• Multiple analysts have recently adjusted their price targets for Omnicell, with a consensus target of $46.71 and a rating of "Moderate Buy."
• Omnicell reported a net margin of 2.01% and earnings of $0.45 per share for the latest quarter, exceeding expectations and showing a 5.0% year-over-year revenue growth.

Cramer Rosenthal Mcglynn LLC boosted its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 27.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 220,276 shares of the company's stock after buying an additional 47,245 shares during the quarter. Cramer Rosenthal Mcglynn LLC owned approximately 0.47% of Omnicell worth $7,701,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Victory Capital Management Inc. raised its position in Omnicell by 10.1% in the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock valued at $58,745,000 after purchasing an additional 154,038 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after purchasing an additional 394,820 shares during the last quarter. Lazard Asset Management LLC raised its position in Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after purchasing an additional 737,536 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in Omnicell by 4.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock valued at $53,290,000 after buying an additional 56,117 shares during the last quarter. Finally, Toronto Dominion Bank acquired a new stake in Omnicell during the 4th quarter worth approximately $30,637,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on OMCL. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Benchmark reduced their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Bank of America raised their target price on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wells Fargo & Company lifted their target price on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Finally, Piper Sandler reduced their price target on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Omnicell currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.71.

Omnicell Trading Up 0.2%

OMCL stock traded up $0.05 during mid-day trading on Thursday, reaching $33.28. The company's stock had a trading volume of 347,117 shares, compared to its average volume of 612,079. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 66.56, a price-to-earnings-growth ratio of 7.26 and a beta of 0.78. The business's 50 day moving average price is $29.98 and its 200 day moving average price is $31.68. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The firm's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.